

InVivo targets \$22B injectable pain-relief market | Regulatory Roundup

Mass Device

InVivo Therapeutics engages the FDA to discuss the regulatory path for its injectable hydrogel for neurological pain, anticipating an annual market potential of \$22 billion.

[InVivo engages the FDA to move forward on injectable pain-relief hydrogen, aims for \\$22B yearly market](#) [1]

[InVivo Therapeutics](#) [2] (OTC:[NVIV](#) [3]) is hoping to break into what may be a \$22 billion annual market with its new combination injectable hydrogel for pain management in the lower back, legs, neck or arms.

Late last month, the company submitted a request to meet with the FDA's Office of Combination Products and the Center for Devices & Radiological Health to discuss the path for the product, a hydrogel engineered for sustained release of therapeutic molecules.

Source URL (retrieved on 02/01/2015 - 8:57am):

http://www.mdtmag.com/news/2012/07/invivo-targets-22b-injectable-pain-relief-market-regulatory-roundup?qt-recent_content=0

Links:

[1] <http://www.businesswire.com/news/home/20120702005385/en/InVivo-Therapeutics-Engages-FDA-Product-Drug-Releasing>

[2] <http://www.massdevice.com/company/invivo-therapeutics-corp>

[3] <http://www.google.com/finance?q=OTC%3ANVIV>